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Abstract
Objective—Chronic obstructive pulmonary disease (COPD) is associated with increased
morbidity and mortality and reduced quality of life. Novel interventions are needed to improve
outcomes in COPD patients. The present study assessed the effects of a telephone-based coping
skills intervention on psychological and somatic quality of life and on the combined medical
endpoint of COPD-related hospitalizations and all-cause mortality.
Methods—We conducted a dual-site, randomized clinical trial with assessments at baseline and
after 16 weeks of treatment. The study population comprised 326 outpatients with COPD aged 38
to 81 years, randomized to Coping Skills training (CST) or to COPD Education (COPD-ED).
Patients completed a battery of quality of life (QoL) instruments, pulmonary function tests, and
functional measures and were followed for up to 4.4 years to assess medical outcomes.
Results—The CST group exhibited greater improvements in psychological QoL compared to
controls (P = .001), including less depression (Cohen’s d=0.22 [95%CI 0.08, 0.36]) and anxiety
(d=0.17 [95%CI 0.02, 0.33]), and better overall mental health (d=0.17 [95%CI 0.03, 0.32]),
emotional role functioning (d= 0.29 [95%CI 0.10, 0.48]), vitality (d= 0.27 [95%CI 0.11, 0.42]),
and social functioning (d= 0.21 [95%CI 0.03, 0.38]). A significant baseline psychological QoL by
Treatment group interaction revealed that CST with lower QoL at baseline achieved even greater
improvements in psychological QoL compared to COPE-ED. CST participants also exhibited
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greater improvements in Somatic QoL (P = .042), including greater improvements in pulmonary
QoL (d= 0.13 [95%CI 0.01, 0.24]), less fatigue (d= 0.34 [95%CI 0.18, 0.50]), and less shortness of
breath (d= 0.11 [95%CI −0.01, 0.23]) and greater improvement in distance walked on the 6
Minute Walk Test (d= 0.09 [95%CI 0.01, 0.16]). However, there was no significant difference in
risk of time to COPD-related hospitalization or all-cause mortality between CST (34 events) and
COPD-ED (32 events) (P= 0.430).
Conclusions—A telehealth coping skills training intervention produced clinically meaningful
improvements in quality of life and functional capacity, but no overall improvement in risk of
COPD-related hospitalization and all-cause mortality.
Trial Registration—clinicaltrials.gov Identifier NCT00736268
Keywords
COPD; stress; depression; coping skills; disease-management
Chronic Obstructive Pulmonary Disease (COPD) is widely recognized as a growing health
problem in this country, affecting an estimated 15 million Americans.(1) COPD
exacerbations are responsible for more than 800,000 hospital admissions in the United States
each year, and there were 143,000 deaths attributed to COPD in 2011, making it the third
leading cause of mortality in the United States.(2) Furthermore, acute exacerbations
accelerate decline in lung function, reduce patients’ quality of life (QoL), and increase
health care use.(3) In recognition of the importance of QoL, the Global Initiative for Chronic
Obstructive Pulmonary Disease (GOLD) included an assessment of pulmonary symptoms in
the revised disease severity assessment.(3)
Given the significant symptom burden and functional impairment associated with COPD, it
is not surprising that studies have consistently documented the high prevalence of
psychological distress among COPD patients compared to the general population.(4) This
distress is apparent in the high rates of anxiety and depression observed in studies of COPD
patients,(5–8) and has a profound adverse impact on QoL and physical functioning.(9–12)
COPD patients with comorbid depression and anxiety report lower QoL,(11) and patients
with greater physical symptoms also experience higher levels of psychological distress.(13)
Increased levels of distress have been shown to be related to impaired functional
capacity(14) over and above disease severity.(15) In fact, QoL is only weakly related to
pulmonary function,(16) and there is evidence that higher levels of distress also may affect
disease progression. (17) Despite the well-documented impact of psychological distress on
the physical and emotional functioning of patients with COPD, these psychological
symptoms commonly remain under-recognized and untreated.(18)
Improving patients’ management of their disease has become increasingly recognized as
being important in optimizing medical outcomes, and patient-centered outcomes are
themselves now considered important therapeutic targets.(19) Disease self-management
refers to patients’ ability to manage their symptoms and to adopt health behaviors that
enhance their QoL. In this manner, self-management requires patients’ active engagement in
managing their own health condition.(20, 21) Although a variety of strategies have been
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used to promote self-management, most studies of COPD patients have relied primarily on
educational approaches, with mixed results.(22) Telehealth interventions in COPD also have
provided inconsistent results, with efforts directed primarily at improving medical
management rather than at improving patients’ ability to manage their own symptoms.(23,
24) Current clinical practice guidelines emphasize smoking cessation, education, pulmonary
rehabilitation, nutrition, oxygen therapy, medications, and, surgery if necessary.(25, 26)
However, few studies have focused on stress reduction or teaching patients strategies for
coping more effectively with their illness.
The goal of the present study was to evaluate the efficacy of a telehealth coping skills
training (CST) intervention for improving QoL and medical outcomes in COPD patients by
helping them develop skills for coping more effectively with their disease. The CST
intervention was initially developed for patients with end-stage lung disease awaiting lung
transplantation. Results of our previous randomized clinical trial (RCT), known as the
Investigational Study of Psychological Intervention in Recipients of Lung Transplant
(INSPIRE) trial,(27) showed that CST improved psychological QoL, but did not improve
somatic QoL or overall survival. In the present RCT, we modified the CST intervention and
extended it to a broader population of COPD patients who are not transplant candidates. In
recognition of the potential value of involving patient caregivers in the treatment program,
(21) we included partners in the intervention whenever possible. Also, in order to potentially
improve functional capacity and reduce somatic symptoms, we included a physical activity
module to include in the CST intervention. Thus, INSPIRE-II sought to determine if a
coping skills intervention, delivered over the telephone, compared to COPD education,
would improve indices of psychological and somatic QoL and improve the combined
medical outcome of all-cause mortality and COPD-hospitalizations in a relatively large
sample of COPD outpatients.
METHODS
Eligibility and Trial Overview
A description of the rationale and methods of the INSPIRE-II trial has been published
previously.(28) INSPIRE-II is a dual-site (Duke University Medical Center and Ohio State
University), RCT of CST versus COPD education in patients diagnosed with COPD, with
FEV1 25–80% of predicted within 6 months of study enrollment; FEV1/FVC <70%; and
capacity to follow study procedures. Participants were required to have a caregiver or
partner to participate unless they were unmarried or had no friends or family members;
patients that had a caregiver who was unwilling to participate were ineligible. The protocol
was approved by the respective Institutional Review Boards at Duke and Ohio State. All
patients voluntarily provided written informed consent. Our first patient was randomized on
January 5, 2009 and the last follow-up was completed May 30, 2013.
Assessment procedures
Patients completed an assessment battery tapping both psychosocial and somatic/physical
QoL domains in the week before and the week following the 16-week telehealth
intervention.
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Psychological Quality of Life
Beck Depression Inventory II (BDI-II): (29) The 21-item BDI-II is a widely used measure
of depression among medical patients and has been shown to have good one-week test-retest
reliability (r = 0.93). BDI-II scores ≥ 14 are suggestive of clinically significant depression.
State-Trait Anxiety Inventory-State (STAI): (30) The 20-item STAI was used to assess
levels of state anxiety. Test-retest reliability has been shown to be high, with 2-month
reliabilities ranging from 0.65 to 0.75. (31) STAI scores ≥ 45 are suggestive of clinically
elevated anxiety in medical patients.(32)
Short Form-36 Health Survey (SF-36): (33) The SF-36 measures psychological QoL in
four domains: social functioning, role limitations due to emotional problems, vitality, and
mental health. The SF-36 has excellent test-retest reliability with coefficients ranging from
0.73 to 0.96 over a two-week period.(34) Higher scores indicate better quality of life.
Somatic Quality of Life
Pulmonary Quality of Life Scale (PQLS): (35) The 25-item PQLS, was designed to assess
health-related QoL among individuals with pulmonary disease. The PQLS has been shown
to have high internal consistency (0.87) and correlates well with other indices of pulmonary
QoL.(36) Higher scores indicate better somatic quality of life.
UCSD Shortness of Breath Questionnaire (SOBQ): (37) The 24-item SOBQ has been
shown to have good reliability, with a test-retest reliability of 0.94, and is highly correlated
with measures of pulmonary function and functional status.(37, 38) Lower scores indicate
less shortness of breath.
Short Form-36 Health Survey (SF-36): The SF-36 is a self-report questionnaire that
measures physical QoL in four domains: physical functioning, role limitations due to
physical problems, pain, and general health perception. The SF-36 has been found to have
excellent test-retest reliability with coefficients generally exceeding 0.85 over a two-week
period. (34)
Brief Fatigue Inventory (BFI): (39) The BFI is a 9-item scale to assess fatigue. All items
are rated on numeric scale from 0 to 10 with higher scores indicating greater fatigue. The
BFI has excellent reliability, with a Cronbach’s alpha of 0.96. Lower scores indicate less
fatigue.
St. George’s Respiratory Questionnaire (SGRQ): (40) The SGRQ is a 50-item scale that
evaluates symptomatology (e.g., frequency of cough, sputum production, wheeze,
breathlessness), activity (activities that cause or are affected by breathlessness), and impacts
(on employment, need for medications, disruption of daily life). The SGRQ has been shown
to have good reliability, with a Cronbach’s alpha of ≥ 0.76.(41) Lower scores indicate better
quality of life.
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Pulmonary Function, Physical Activity, and Exercise Tolerance—Spirometry
was performed in accordance with guidelines established by the American Thoracic Society.
(42) Patients also completed a standard Six-Minute Walk test (6MWT)(43) to determine
exercise tolerance by measuring the distance that patients were able to walk within a 6-
minute time limit at a self-selected pace, with adequate oxygen to maintain saturations of
90% or greater. The Charlson Medical Comorbidity Index(44) was used to assess the
cumulative burden of medical comorbidity. In addition, the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) system was used to classify patients into risk categories
labeled A-D based on FEV1 and self-reported respiratory symptomatology.(45, 46)
Staff performing each of these assessments was blinded to treatment condition.
Miscellaneous Questionnaires
Brief COPE: (47) The 28-item COPE was used to assesses dispositional coping and has
been found to have good reliability, with indices generally exceeding 0.60.(48) For the
purposes of this study, we identified 3 factors: Active coping, Disengagement, and Support
Seeking.
Perceived Social Support Scale (PSSS): (49) The 12-item PSSS measures perceived
support from family and friends and has good test-retest reliability, with coefficients
exceeding 0.70. (50) Higher scores indicate greater perceived support.
CHAMPS Activities Questionnaire: (51) The CHAMPS is a self-report measure of
physical activity that was used to quantify patients’ typical activity level and to develop
activity recommendations for the CST intervention. The CHAMPS has good test-retest
reliability with coefficients for most indices exceeding 0.60. (52)
Marital Satisfaction Inventory: (53) For the subset of patients who had partners or
caregivers, we administered the Affective Communication and Problem Solving subscales
from the Marital Satisfaction Inventory, which has a test-retest reliability of 0.89. (54)
Caregiver Strain Index: (55) In recognition of the psychological impact of caregiving for
patients with COPD,(56) caregivers completed the 13-Item Caregiver Strain Index, which
assesses a variety of stressors commonly experienced by caregivers.(57) The Caregiver
Strain Index has an internal reliability of 0.86. (55)
Medical Endpoints—Patients documented all medical encounters every 6 months.
Medical records were reviewed by a physician assistant and a consensus conference of
pulmonologists, blinded to treatment condition, adjudicated all medical events. The primary
medical endpoint was defined as the combined endpoint of time to death from any cause or
first COPD-related hospitalization.
Telehealth Interventions
Patients were randomized 1:1 either to Coping Skills Training (CST) or to COPD education
(COPD-ED). Randomization was performed centrally by computer with conditional
randomization (stratified by availability of a caregiver, FEV1, gender, and current smoking
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status) separately by site. Medications and other general aspects of COPD management were
left to the discretion of participants’ primary care providers and/or pulmonologists.
Coping Skills Training—CST provided instruction in cognitive-behavioral coping skills
delivered to patients and partners over the telephone by clinical psychologists weekly for 12
weeks and biweekly for 1 month (14 sessions total over 16 weeks). The interventionists
received training in the delivery of the CST intervention by experienced clinical
psychologists (FJK, VO’H, JAB) who provided weekly supervision throughout the trial.
Sessions were audiotaped and each audiorecording was reviewed using criteria for treatment
fidelity (e.g., appropriate delivery of key session components, appropriate use of time in
session) and therapist competence (e.g., use of interviewing skills, eliciting patient
engagement, dealing with resistance) using procedures that we employed previously. (27)
Each therapist was credentialed on pilot subjects for each of the 14 sessions prior to
delivering the session to a study participant.
The CST protocol was manualized and included four components: 1) education about stress
and pulmonary health; 2) training in a variety of coping skills (e.g., relaxation, problem-
solving, cognitive restructuring); 3) promotion of physical activity (an individualized
activity prescription based on FEV1 values, Charlson Comorbidity Index Score, and baseline
6MWT performance, along with self-reported activities on the CHAMPS questionnaire was
used to make personalized activity recommendations); and 4) maintenance and
generalization. Caregivers participated fully in all sessions to facilitate communication
between the patient and caregiver regarding the use of coping strategies to control symptoms
and reduce distress, to prompt and reinforce patients’ efforts to cope with COPD symptoms,
and promote adherence to prescribed homework assignments. Each session was designed to
last for 30 minutes.
COPD Education—Participants in COPD-ED received their usual care through their local
physicians. Patients and their respective caregivers also received COPD education delivered
via a series of 12 weekly and 2 biweekly telephone calls from a health educator (JJJ) with
experience in the management of COPD. Each session began with a brief medical review of
the prior week that provided patients (and caregivers) with an opportunity to discuss the
patient’s current treatment and symptoms. Each of the weekly educational discussions
focused on a topic relevant for COPD management and included such topics as pulmonary
physiology, medication usage, nutrition, and symptom management. The COPD-ED
intervention was designed to provide attention, support, and relevant information about
COPD, without providing instruction in specific coping strategies. Caregivers were
encouraged to participate fully in all discussions.
Statistical analysis
Treatment effects on psychological and somatic QoL were evaluated using linear models
with maximum likelihood estimation available in Muthen’s Mplus software.(58) The latent
variable Psychological QoL was comprised of scores on the BDI-II, STAI, SF-36 Mental
Health, SF-36 Emotional Functioning, SF-36 Vitality, and SF-36 Social Functioning. The
Somatic QoL latent variable was comprised of scores on the PQLS, SGRQ, BFI, SOBQ,
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SF-36 Physical Role, SF-36 General Health, SF-36 Physical Functioning, and SF-36 Pain.
Treatment group was the primary effect of interest, and age, gender, race, treatment site,
oxygen utilization, FEV1, and the corresponding baseline level of the outcome variable were
included as adjustment covariables. If the latent variable model showed a significant
treatment effect, follow-up analyses were conducted using the general linear model for each
separate indicator of that latent variable. The primary models followed the intention-to-treat
principle using the full information maximum likelihood method for managing missing data,
available in Mplus.(59) Patients with and without an available caregiver were analyzed
separately, but because the results were essentially the same, patients were combined in the
reported analyses. Effect sizes for group differences were calculated using Cohen’s d.(60)
We evaluated the effects of treatment on medical events with a logrank test for time to death
or first hospitalization during the follow-up period. In this analysis, we used Cox regression,
with the first clinical event coded as the event, and those participants with no events or who
dropped out were censored at the time of last contact. We evaluated the extent to which
models met assumptions, including additivity, linearity, and distribution of residuals. We
found no evidence of significant violations of these assumptions.
RESULTS
Patient Characteristics
A total of 434 patients were initially considered eligible for the trial (Figure 1); 36 were
classified as medically unstable, 30 were excluded because they were found not to have
COPD by spirometric criteria, 24 declined to participate, 17 were excluded because their
caregiver was unwilling to participate, and one was excluded because of advanced age,
leaving 326 patients available for randomization: 162 patients were randomly assigned to
CST and 164 were assigned to COPD-ED. Two hundred fifty-two individuals had a
caregiver (77%); 63 participants from OSU had a caregiver (64%) and 189 participants from
DUMC had a caregiver (83%); 74 patients without an identified caregiver were randomized
and included in the analyses.
The mean age of the sample was 66.1 years and the majority of patients were Caucasian.
The treatment groups were similar on background characteristics, including age, gender,
ethnicity, and medical background variables including FEV1 and performance on the 6MWT
(Table 1).
Treatment Adherence
Attendance on CST phone calls ranged from one to 14 sessions. The median number of
completed sessions was 14 (100%); for COPD-ED, the median number of completed
sessions also was 14 (100%). For CST, sessions averaged 32.6 minutes (SD=4.7) with a
median of 32.2 minutes. For COPD-ED, sessions averaged 10.8 minutes (SD=4.7) with a
median of 9.9 minutes. Twenty-two participants (6.7%) dropped out during the course of the
study (13 in CST and 9 in COPD-ED); three participants died during the intervention period,
all of whom were in COPD-ED.
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Psychological Quality of Life Outcomes
The pre- and post-treatment means for Psychological QoL are presented in Table 2 along
with post-treatment group contrasts, adjusting for age, gender, race, FEV1, oxygen use,
treatment site, and the corresponding baseline level of the outcome variable. The CST group
exhibited greater improvements in Psychological QoL compared to participants in COPD-
ED (P = .001). Participants in the CST group exhibited less depression (d=0.22 [95%CI
0.08, 0.36]; P = .002) and anxiety (d=0.17 [95%CI 0.02, 0.33]; P= .030), and better overall
mental health (d=0.17 [95%CI 0.03, 0.32]; P = .021), emotional role functioning (d= 0.29
[95%CI 0.10, 0.48]; P = .003), vitality (d= 0.27 [95%CI 0.11, 0.42]; P <.001), and social
functioning (d= 0.21 [95%CI 0.03, 0.38]; P = .023).
Moderation—In addition to the overall treatment main effect for Psychological QoL, we
also observed a significant baseline QoL by treatment group interaction (P = .037),
indicating that there was a differential treatment response as a function of baseline levels of
Psychological QoL. CST patients with lower Psychological QoL at baseline attained even
greater improvements compared to COPD-ED patients (Figure 2). It is noteworthy, that the
effect sizes for participants with low baseline QoL were moderate to high, suggesting
clinically, as well as statistically, significant treatment group differences. For example,
participants with baseline BDI-II scores ≥ 14 in CST showed greater reductions in
depressive symptoms (Mdiff = 4.6 [SE±1.1]) compared to COPD-ED controls (Mdiff = 1.0
[SE=±1.2]) (d=0.46 [95%CI 0.14, 0.78], P = .006), whereas reductions in depressive
symptoms were smaller among participants with BDI-II scores <14 (d = 0.22 [95%CI 0.00,
0.43], P = .048). Similarly, treatment effects were greater for individuals with clinically
elevated anxiety (d = 0.66 [95%CI 0.13, 1.20], P = .019) compared to participants with
STAI scores <45 (d=0.05 [95%CI −0.10, 0.21], P = 507). CST participants with baseline
STAI scores ≥45 achieved a 10.6-point reduction (SE = ± 2.0) on the STAI compared to
only a 3.1-point reduction (SE= ± 2.1) in COPD-ED patients with baseline STAI scores ≥45.
The observed effects of treatment on psychological QoL were not moderated by age (P = .
777), gender (P = .469), baseline FEV1 (P = .833), or treatment site (P = .181).
Somatic Quality of Life Outcomes
Compared to COPE-ED, patients in CST exhibited greater improvements in Somatic QoL (P
= .042). The pre- and post-treatment means and adjusted post-treatment group contrasts for
Somatic QoL are presented in Table 3. Examination of separate somatic symptom measures
revealed that participants in the CST group showed greater improvements in PQLS (d= 0.13
[95%CI 0.01, 0.24]; P = .040), less fatigue (d= 0.34 [95%CI 0.18, 0.50]; P < .0001), and less
shortness of breath as measured by the St. George’s Respiratory Questionnaire (d= 0.11
[95%CI −0.01, 0.23]; P= .068), but not the San Diego SOBQ (d= −0.01 [95%CI −0.12,
0.10];P = .859) compared to COPD-ED. There were no treatment group differences for
SF-36 pain (d=0.01 [95%CI −0.16, 0.17];P= .947), SF-36 physical role (d= 0.10 [95%CI
0.08, 0.27]; P = .286), SF-36 general health (d= 0.09 [95%CI −0.05, 0.22]; P = .217), or
SF-36 physical functioning (d= 0.07 [95%CI −0.05, 0.19]; P = .224). The observed
treatment effects on Somatic QoL were not moderated by baseline somatic symptoms (P= .
490), age (P = .388), gender (P = .176), baseline FEV1 (P = .205), or treatment site (P = .
130).
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Pulmonary Function and Functional Status Outcomes
CST participants demonstrated greater improvement in distance walked on the 6MWT (d=
0.09 [95%CI 0.01, 0.16]; P = .030) compared to COPD-ED following treatment (Table 4).
Participants in the CST group reported greater total activity (d= 0.19 [95%CI 0.00, 0.38]; P
= .045) and total caloric expenditure (d= 0.21 [95%CI 0.03, 0.38] P = .022) on the
CHAMPS compared to COPD-ED. There were no group differences with respect to changes
in FEV1 (d= 0.01 [95%CI −0.09, 0.12]; P = .796).
Additional Psychosocial Outcomes
The CST group also reported greater social support (M= 66.4 [95%CI 63.9, 69.0] vs. 63.2
[95%CI 60.6, 65.7]; P = .018) following treatment and, for those participants with a
caregiver, greater improvements in communication as measured by the Marital Satisfaction
Inventory Affective Communication (CST: M= 2.9 [95%CI 2.4, 3.3] vs. COPD-ED: 3.7
[95%CI 3.3, 4.1]; P = .011) and Problem Solving subscales (CST: M = 6.0 [95%CI 5.3, 6.6]
vs. COPD-ED: 7.2 [95%CI 6.6, 7.8], P = .008) compared to patients in COPD-ED. Among
caregivers, there were no treatment group differences in caregiver strain (CST: M= 5.4
[95%CI 4.5, 6.3] vs. COPD-ED: 5.1 [95%CI 4.3, 6.0]; P = .531).
Changes in Coping
In order to examine treatment effects on coping skills, we examined the impact of treatment
on three latent coping variables, which were determined by maximum-likelihood factor
analysis. A factor analysis yielded three coping latent variables, which we labeled Active
coping, Disengagement, and Support Seeking. The Active coping (hereafter referred to as
Active) was comprised of the Active, Planning, Acceptance, and Positive Reframing
subscales from the COPE. The Disengagement latent variable was comprised of the
Behavioral Disengagement, Blame, Denial, and Venting subscales. The Support Seeking
latent variable was comprised of the Emotional Support Seeking, Instrumental Support
Seeking, and Religion subscales. The loadings of the indicators for the coping variables
ranged from .50 to .87 at both pre- and post-treatment assessments, with three minor
exceptions (the Religion subscale loaded with the Support Seeking latent variable .37 before
treatment and .32 after treatment and the Venting subscale loaded on the Disengagement
latent variable at .44 before treatment. Although these loadings were not very strong, we
allowed them to remain as indicators of their respective latent variables).
Examination of changes in coping styles revealed that the CST group showed greater
improvements in the Active (P < .001) and Support Seeking latent variables (P = .005), but
not on the Disengagement latent variable (P= .649). CST participants showed improvements
in the Active (d = .30 [95%CI 0.21, 0.50], P = .003), Seeking Instrumental Support (d = 0.21
[95%CI 0.01, 0.41], P = .044), Seeking Emotional Support (d = 0.25 [95%CI 0.07, 0.43], P
= .008), Acceptance (d = 0.33 [95%CI 0.13, 0.53], P = .002), Positive Reframing (d = 0.28
[95%CI 0.08, 0.47], P = .006), Distraction (d = 0.24 [95%CI 0.05, 0.44], P = .016), Blaming
(d = 0.17 [95%CI −0.01, 0.34], P = .064) and Planning (d = 0.19 [95%CI −0.01, 0.38], P = .
067) compared with COPE-ED participants (Table 5). In contrast, the groups did not differ
in use of Religion (d = 0.02 [95%CI −0.11, 0.15], P = .726), Venting (d = 0.13 [95%CI
−0.06, 0.31], P = .192), Denial (d = 0.06 [95%CI −0.14, 0.26], P = .529), Behavioral
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Disengagement (d = 0.05 [95%CI −0.16, 0.25], P = .659), Substance Use (d = 0.04 [95%CI
−0.13, 0.27], P = .656), or Humor (d = 0.08 [95%CI −0.12, 0.27], P = .451).
Mediational Analyses
We examined changes in coping style, as measured by the Brief COPE Inventory, as a
potential mediator of the relationship of treatment group and Psychological QoL, while
changes in 6MWT distance was considered as a potential mediator of treatment group and
Somatic QoL. When the mediating paths (COPE latent variables) were included in the
model, the direct effect of CST on Psychological QoL persisted (standardized coefficient = .
12, P = .002); there was minimal evidence that the impact of CST on psychological QoL
was mediated by improved by Active coping (P = .848), Disengagement (P = .617), or
Support Seeking (P = .096).
In contrast, when the mediating path from CST to 6MWT to Somatic QoL was included in
the model, the direct effect of CST on Somatic QoL was no longer significant (standardized
coefficient = .07, P =.213), suggesting that the impact of CST on improved Somatic QoL
was mediated by improvements in 6MWT (P = .032).
Survival and Medical Event Outcomes
Follow-up time varied from 0.4 to 4.4 years with a median follow-up time of 2.5 years (SD
= 1.04 years). There were 11 deaths over the course of the study, 3 in CST and 8 in COPD-
ED. For time-to-event analyses, there were 34 first events in CST group and 32 in the
COPD-ED group. There was no difference between CST and COPD-ED in time to death or
first COPD-related hospitalization (P = .430) (Figure 3).
DISCUSSION
COPD is a chronic and debilitating condition that affects millions of Americans and results
in significant impairments in emotional well-being, physical functioning, and quality of life,
as well as increased morbidity and mortality. Psychological distress negatively impacts
quality of life, (9, 10) and functional capacity(14) and promotes disease progression (17) and
risk for mortality in patients with COPD.(61) In an effort to improve QoL, reduce distress,
and improve clinical outcomes, we conducted a dual-site, RCT to evaluate the effects of a
partner-assisted telehealth coping skills training intervention in COPD patients. Although
CST did not improve the combined medical endpoint of COPD-related hospitalization and
all-cause mortality compared to COPD-ED, CST was associated with significant
improvements in psychosocial QoL, including reduced depression and anxiety, greater
vitality, improved social and emotional role functioning, and better overall mental health.
For those participants with caregivers, patients in CST reported greater improvement in
communication compared to patients in COPD-ED, which is considered important because
COPD is known to adversely affect partner communication.(62, 63) CST participants also
reported greater improvements in somatic QoL compared to COPD-ED, reporting less
fatigue and shortness of breath and increased functional capacity as measured by the 6MWT
and increased physical activity as measured by the CHAMPS. The CST intervention
employed in INSPIRE II encouraged increased physical activity, which appeared to enhance
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the effectiveness of CST in improving QoL. Indeed, regular exercise is a key component of
pulmonary rehabilitation and has been shown to improve QoL and functional capacity in a
number of studies.(64–67) Furthermore, mediational analyses revealed that improved
functional capacity contributed to the improvements in somatic symptoms and somatic QoL
achieved by CST participants.
The improvements in QoL for CST compared to COPD-ED were statistically significant;
however, the effect sizes were relatively modest, and generally were in the range of d= 0.2
to 0.4. Because INSPIRE-II recruited COPD patients regardless of their initial level of
distress and QoL at study entry, the effect sizes for the entire sample do not fully capture the
clinical value of treatment. The baseline psychological QoL by treatment group interaction
revealed that patients who entered the trial with diminished psychological QoL benefitted
the most from CST. CST patients with greater distress at study entry achieved clinically, as
well as statistically, significant improvements. For example, CST patients who obtained
baseline BDI-II scores ≥14 had a 4.6-point reduction compared to only 1.0-points for
patients in COPD-ED; the effect size was d= 0.46. Similarly, patients who obtained STAI
scores ≥45 at study entry had a 10.6-point reduction if they were in CST compared to a 3.1-
point reduction if they were in COPD-ED; the effect size was d= 0.66.
These improvements in anxiety and depression in our sample are especially noteworthy.
Despite the high prevalence of depression in COPD,(68) less than half of depressed COPD
patients are diagnosed and less than a third receive treatment.(18) In a review of treatments
for depression in COPD patients, Fritzche et al.(69) noted that pharmacological and
behavioral treatments in COPD patients were rare and inconsistent. Moreover, the small
number of studies and poor methodologies contributed to heterogeneous results. In one of
the better designed studies, Hynninen et al.(70) found CBT to improve depressive symptoms
and Kunik et al.(71) reported that a single session of CBT reduced depressive symptoms in
mildly depressed COPD patients. De Godoy and colleagues(72) reported that
psychotherapy, when combined with pulmonary rehabilitation, showed improvements in
anxiety, depression, QoL and functional capacity. Our findings demonstrate that a CST
intervention also may be an effective treatment for patients with elevated depressive and
anxiety symptoms who aren’t necessarily seeking psychiatric treatment for their distress.
Because there were many components to the CST intervention, it is not possible to
determine which aspects of the program were most beneficial. In a cross sectional study,
Scharloo et al.(73) studied 171 COPD outpatients in the Netherlands and found that illness
representations, but not necessarily perceived control, were associated with improved QoL
and suggested that interventions designed to discuss patients’ illness beliefs as well as
helping patients develop behavioral skills to both manage their illness and cope more
effectively with stress were likely to be most helpful. Although patients in CST improved
their coping skills as evidenced by their higher scores on the Active and Support latent
variables of the Brief COPE, mediational analyses provided little evidenced that improved
coping was responsible for improved psychological QoL. The mechanisms responsible for
the benefits of CST on psychological QoL remain uncertain.
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There have been numerous reviews of telehealth interventions in COPD. McLean et al.(23)
reviewed over 220 published reports consisting of 10 trials and 1004 patients. The
interventions generally provided symptom management for COPD, without specific training
in coping skills. Results indicated a reduction in emergency department visits and
hospitalizations, but no reduction in mortality and no improvement in QoL compared to
controls. In their review of home telemonitoring for COPD, Bolton and colleagues (24)
identified only 2 randomized trials; however, methodological shortcomings, small sample
sizes, and lack of detailed descriptions of the interventions led the authors to conclude that
the benefits were inconclusive. Moreover, the interventions were geared to promote a
response from health providers, presumably to reduce the risk of hospitalization by early
intervention, rather than to teach patients skills to better manage their symptoms.
In a review of 6241 publications involving home telehealth, Polisena et al.(74) identified
only nine original studies, including 858 COPD patients, of which four studies compared
home telemonitoring with usual care and six RCTs compared telephone support with usual
care. Only two RCTs were considered high quality. Clinical heterogeneity was present in
many of the outcomes measured. Surprisingly, the mortality rates were greater in the
telephone-support group compared with usual care (risk ratio = 1.21; 95% CI: 0.84 to 1.75),
but telehealth interventions were similar or better than usual care for QoL and patient
satisfaction outcomes. The interventions represented a mix of treatments and none
specifically included training in coping skills.
In a review of educational programs for patients with COPD, Stoilkova, Janssen and
Wouters (22) extracted 81 articles describing 67 educational interventions. In two-thirds of
the studies, the topic of stress management was discussed. Most educational programs were
delivered in an outpatient hospital setting, while a third were provided by telephone calls
from nurses and less than 5% were delivered over the internet or using telehealth
technology. The authors did not comment on which educational topics contributed to
behavior change and optimal disease management, and did not compare the various modes
by which education were delivered. The lack of consistency in results across studies was
attributed to variations in study design, diversity in interventions and outcome measures, and
important methodological flaws that characterized many studies.
Lemmens, Nieboer, and Jijsman(75) conducted a systematic review of multiple disease-
management interventions in asthma and COPD. Thirty-six studies met their inclusion
criteria, with studies often comparing an education-based intervention for patients and/or
health professionals such as physicians or pharmacists in combination with case
management to usual care. Because of the heterogeneity of patient groups and interventions,
and the inconsistent pattern of results, it was difficult to draw any firm conclusions. No
differences were noted between intervention and control groups on lung function or
symptoms, although multiple interventions tended to be associated with greater
improvements in QoL and reduced hospitalizations, but not in the number of emergency
department visits.
A review by Niesink and colleagues (76) identified 10 education interventions, nine of
which also included exercise training. Other elements of the programs included support,
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relaxation training, smoking cessation, breathing retraining, recreational activities and
occupational therapy. None specifically involved coping skills training, however. Five of the
10 studies showed positive effects on at least one of the measures of QoL compared to
controls. However, it was noted that all of the trials were small (N<30 participants per
group) and involved pulmonary rehabilitation, which has been shown to be effective in
improving QoL regardless of whether it was part of integrated care.
Similarly, in a meta analysis of 23 RCTs of pulmonary rehabilitation, Lacasse (64) also
showed improved QoL, irrespective of whether or not participants were part of integrated
care. Several RCTs are especially relevant to the present study. Walters and colleagues(77)
randomized 182 adults with COPD to a health mentoring intervention delivered by
community nurses or to usual care and brief telephone calls. The health mentoring consisted
of a series of 16 30-minute phone calls over 12 months that targeted smoking, nutrition,
alcohol, physical activity, psychological well-being, and symptom management. Patients in
the control group received their usual care and monthly phone calls from a research nurse.
Results showed that disease self-management was improved relative to the control group,
but there was no difference in QoL. However, only a completers analysis was performed,
and the health mentoring group had a high rate of dropout and non-adherence, completing a
median of only 9 of 16 phone calls.
In another RCT of 115 patients with either heart failure (HF) or COPD, Gellis and
colleagues(78) reported that a multifaceted 3-month “tele-HEART” intervention improved
QoL and reduced emergency department visits after 12 months relative to usual care. The
telehealth monitoring system was provided to patients to improve their self-management of
their disease and patients obtained counseling about the importance of daily monitoring of
body weight, smoking cessation, behavioral activation, diet, medication adherence, problem
solving strategies on managing their medication and monitoring symptoms that could reflect
worsening HF. Results revealed that the telehealth intervention group reported greater
improvements in general health and social functioning and reduced depressive symptoms
compared to the usual care plus education group. Only 27 COPD patients were included in
the study, however, and only a completers analysis was performed. Because COPD and HF
patients were combined, it was not possible to determine the benefits of the intervention in
the subgroup of COPD patients.
Emery and colleagues(79) randomized 79 COPD patients to 10 weeks of exercise, education
and stress management; education and stress management; or to a wait list control group.
Stress management and education did not improve depressive or anxiety symptoms or health
QoL compared to usual care, but the addition of exercise to stress management resulted in
greater benefits compared to either stress management without exercise or to wait list
controls. The exercise intervention was highly intensive (4–5 hours/day), involving daily
supervised exercise for 5 weeks followed by intensive exercise 3 days per week for an
additional 5 weeks. Because exercise was not offered without stress management, however,
it could not be determined if exercise alone would have produced these same benefits.
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By design, participants in the CST intervention spent on average 20 minutes longer on the
telephone (30 min vs 10 min) compared to COPD-ED. Although we intended the COPD-ED
condition to provide a brief, standardized program that would simulate real-world clinical
practice, it is possible that the additional time on the telephone may have contributed to
greater QoL benefits for the CST group. We also note that the patients in COPD-ED also
showed improvements in psychological and somatic QoL, although not to the extent of CST
on most measures. Education itself has been shown to be beneficial (80), and Gadoury et al.
(81) reported that an education program that also included “skill-oriented” teaching, resulted
in reduced hospitalizations over a 2-year follow-up period compared to standard care
controls. In light of these data, it is possible that both groups in our study may have
improved their QoL and may have had less healthcare utilization than they would have
received usual care without any telehealth intervention. We did not monitor medication use
throughout the trial, so that the extent to which medication use contributed to the results
could not be determined. We also did not perform an economic analysis and the cost-
effectiveness of the CST intervention was not assessed.
Our study design also did not permit determination of which components of the CST
intervention may have been most effective. Exercise programs for COPD patients have been
shown to improve QoL, and the extent to which our relatively simple prescription for
increasing physical activity may have contributed significantly to the improvements in QoL
could not be determined. Although the CST intervention reduced psychological distress,
improved somatic symptoms and functional capacity, CST did not result in fewer deaths or
COPD-related hospitalizations. The premise that improved psychological function would
lead to better COPD-related medical outcomes remains unconfirmed at this time.
In summary, this relatively brief, manualized coping skills training program delivered over
the telephone improved patients’ psychological and somatic QoL. Although the intervention
did not reduce all-cause mortality and COPD-related hospitalizations, the beneficial effects
on quality of life and functional status, especially among those patients who were
experiencing high levels of distress, should not be minimized. This intervention can be
easily incorporated into the routine care of COPD patients for whom more traditional mental
health services may not be readily available.
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Flow of participants from initial recruitment to end of treatment. ITT = intention-to-treat.
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Post-treatment Psychological Quality of Life (QoL) as a function of pre-randomization
composite index of Psychological QoL.
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Unadjusted Kaplan-Meier curves showing treatment and all-cause mortality or COPD-
related hospitalizations. CST and COPD-ED participants did not differ in time to first
medical event (P = .430).
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Table 1
Baseline cohort characteristics by treatment group.
Variable COPE-ED (N = 164) CST (N= 162) Full Cohort
Age, yrs, mean (SD) 66.6 (8.7) 65.6 (7.9) 66.1 (8.3)
Male N (%) 98 (60) 101 (62) 199 (61)
Caucasian, N (%) 144 (88) 141 (87) 285 (87)
Education ≥ HS, N (%) 137 (84) 143 (89) 280 (86)
Annual Income > $50K, N (%) 59 (36) 52 (32) 111 (34)
Married, N (%) 103 (63) 93 (58) 196 (60)
Caregiver Identified, N (%) 128 (78) 124 (77) 252 (77)
Charlson Index, median (IQR) 2.0 (3.0) 2.0 (2.0) 2.0 (2.0)
Smoking status, N (%)
 Never 7 (4) 6 (4) 13 (4)
 Current 28 (17) 30 (19) 58 (18)
 Former 129 (79) 124 (77) 253 (78)
Body Mass Index, kg/m2, mean (SD) 28.6 (6.6) 29.1 (6.4) 28.9 (6.5)
FEV1, Liters, mean (SD) 1.36 (0.62) 1.34 (0.61) 1.35 (0.62)
FEV1, % predicted, mean (SD) 46.0 (16.8) 44.7 (16.7) 45.4 (16.8)
6MW Distance, meters, mean (SD) 353.1 (112) 356.7 (115) 354.9 (113)
Forced Vital Capacity (FVC) 2.71 (1.04) 2.71 (0.93) 2.71 (0.99)
FEV1 / FVC 0.51 (0.14) 0.50 (0.15) 0.50 (0.15)
CHAMPS Physical Activity, mean (SD)
 Total Activity, hours/week 10.5 (9.3) 10.0 (9.0) 10.2 (9.2)
 Moderate Activity, hours/week 5.4 (6.7) 4.9 (5.8) 5.1 (6.2)
 Total Caloric expenditure/week 2807 (2667) 2827 (3048) 2816 (2859)
Supplemental Oxygen Usage, N (%) 62 (38) 57 (35) 119 (37)
Duration of COPD, N (%)
 < 1 year 26 (16) 24 (15) 50 (16)
 1–4 years 59 (36) 43 (27) 102 (32)
 5–8 years 35 (21) 44 (28) 79 (25)
 9+ years 44 (27) 47 (30) 91 (28)
GOLD Classification, N (%)
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Variable COPE-ED (N = 164) CST (N= 162) Full Cohort
 A 16 (10) 13 (8) 29 (9)
 B 44 (28) 49 (30) 93 (29)
 C 8 (5) 7 (4) 15 (5)
 D 92 (58) 92 (57) 184 (57)
History of Pulmonary Rehabilitation, N (%) 60 (38) 59 (37) 119 (37)
Medications
Beta blockers, N (%) 34 (21) 46 (28) 80 (25)
ACE Inhibitors, N (%) 45 (27) 58 (36) 103 (32)
ARBs, N (%) 29 (18) 19 (12) 48 (15)
Aspirin, N (%) 66 (40) 72 (44) 138 (42)
Asthma Medications, N (%) 14 (9) 11 (7) 25 (8)
Other Antiplatelets, N (%) 12 (7) 10 (6) 22 (7)
Cholesterol-Lowering, N (%) 74 (45) 71 (44) 145 (45)
Nitrates, N (%) 6 (4) 5 (3) 11 (3)
LABA, N (%) 113 (69) 104 (64) 217 (67)
LAMA, N (%) 73 (45) 84 (52) 157 (48)
SABA, N (%) 123 (75) 116 (72) 239 (73)
SAA, N (%) 44 (27) 35 (22) 79 (24)
Inhaled Corticosteroids, N (%) 114 (70) 106 (65) 220 (67)
Psych Meds, N (%) 72 (44) 64 (40) 136 (42)
 Anxiolytic, N (%) 34 (21) 27 (17) 61 (19)
 Sleep, N (%) 10 (6) 10 (6) 20 (6)
 SSRI, N (%) 31 (19) 32 (20) 63 (19)
 Other Depression, N (%) 16 (10) 18 (11) 34 (10)
Diabetes, N (%) 21 (13) 22 (14) 43 (13)
Diuretic, N (%) 34 (21) 27 (17) 61 (19)
ACE inhibitors = Angiotensin Converting Enzyme Inhibitors, ARBs = Angiotensin II Reactor Antagonists, COPD = chronic obstructive pulmonary
disease, FEV1 = forced expiratory volume in 1 second, ICS = Inhaled Corticosteroids, IQR = interquartile range, LABA = Long Acting Beta
Agonist, LAMA = Long Acting Muscarinic Antagonist, SAA = Short Acting Anticholinergic, SABA = Short Acting Beta Agonist, SD = standard
deviation, SSRI = selective serotonin reuptake inhibitor.
*
Due to incomplete data for some assessments, the total number of participants may not add up to 326 in all cases.
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